학술논문

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.
Document Type
Article
Source
Investigational New Drugs; Feb2023, Vol. 41 Issue 1, p93-104, 12p
Subject
INTRAVENOUS therapy
FEVER
ADRENOCORTICAL hormones
B cells
MONOCLONAL antibodies
KILLER cells
SHIVERING
DOSE-effect relationship in pharmacology
ITCHING
RESEARCH funding
TUMORS
FATIGUE (Physiology)
HEADACHE
CHEMOKINES
T cells
PATIENT safety
ADULTS
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)